Liver-protective and stimulant drug
Bisorcic Other names N 2 ,N 5 -Diacetyl-L -ornithine; N 2 ,N 5 -Diacetylornithine; N α ,N δ -DiacetylornithineRoutes of administration Oral [ 1] Drug class Hepatoprotective agent ; Psychostimulant [ 2] [ 1]
(2S )-2,5-diacetamidopentanoic acid
CAS Number PubChem CID ChemSpider UNII ChEBI ChEMBL Formula C 9 H 16 N 2 O 4 Molar mass 216.237 g·mol−1 3D model (JSmol )
CC(=O)NCCC[C@@H](C(=O)O)NC(=O)C
InChI=1S/C9H16N2O4/c1-6(12)10-5-3-4-8(9(14)15)11-7(2)13/h8H,3-5H2,1-2H3,(H,10,12)(H,11,13)(H,14,15)/t8-/m0/s1
Key:XUYANFPPYJSBPU-QMMMGPOBSA-N
Bisorcic (INN Tooltip International Nonproprietary Name ), also known as N 2 ,N 5 -diacetyl-L -ornithine , is a drug described as a hepatoprotective agent and "psychostimulant " which has been used in France in the treatment of asthenia .[ 2] [ 3] [ 4] [ 5] [ 1] It is the N 2 ,N 5 -diacetylated derivative of the amino acid L -ornithine .[ 6]
Bisorcic was first described in the literature in 1973 in a German patent .[ 2] The INN Tooltip International Nonproprietary Name was designated around 1975.[ 7] The drug was marketed in France by Astyl-Gallier in 1987.[ 1] It was provided in the form of 200 mg oral capsules and four capsules were taken daily.[ 1]
L -Ornithine, as the combination drug L -ornithine L -aspartate (LOLA), has been used in the treatment of hepatic encephalopathy and cirrhosis and is likewise described as hepatoprotective.[ 8] [ 9] It is thought to work by participating in the urea cycle and lowering ammonia levels.[ 8] [ 9]
^ a b c d e Schlesser JL (1990). Drugs Available Abroad: A Guide to Therapeutic Drugs Available and Approved for Use Outside the U. S. Gale Research; Derwent Publications Ltd. p. 24. ISBN 978-0-8103-7177-4 . Retrieved 28 September 2024 . 109 BISORCIC. Countries Where Available and Release Dates: France (1987). Brand Names and Manufacturers: Astyl-Gallier (France). Drug Action: Psychostimulant. Indications/Usage: Asthenia. How Supplied: 200 mg capsules. Dosage: 4 capsules daily. Not recommended in children. Contraindications: Epilepsy.
^ a b c Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies . Springer US. p. 906. ISBN 978-1-4757-2085-3 . Retrieved 28 September 2024 . Nα ,Nδ -Di-Ac: [39825-23-5]. N2 ,N5 -Diacetylornithine, 9Cl. Bisorcic, INN. 69H16N2O4. M 216,236. Hepatoprotective agent, psychostimulant. [...] Ger. Pat. , 2 219 874, (1973 ); CA , 78 , 98010t (Bisorcic ).
^ Buckingham J (2020). Dictionary of Natural Products . CRC Press. p. 356. ISBN 978-1-000-15302-6 . Retrieved 28 September 2024 .
^ Blunt JW, Munro MH (2007). Dictionary of Marine Natural Products with CD-ROM . CRC Press. p. 522. ISBN 978-0-8493-8217-8 . Retrieved 28 September 2024 .
^ Negwer M (1994). Organic-chemical Drugs and Their Synonyms: (an International Survey) . Akademie Verlag. p. 359. ISBN 978-3-05-500156-7 . Retrieved 28 September 2024 . 6220. 39825-23-5 CI CI -NH2 N C10H10CI2N2O2 51 230-28-5. N2,N5-Diacetyl-L-ornithine. R see also no. 3704. S Bisorcic**. U Psychostimulant.
^ "Bisorcic" . PubChem . U.S. National Library of Medicine. Retrieved 28 September 2024 .
^ "Proposed International Nonproprietary Names (Prop. INN): List 34. International Nonproprietary Names for Pharmaceutical Substances" (PDF) . Supplement to WHO Chronicle . 29 (9). 1975. Retrieved 28 September 2024 .
^ a b Kircheis G, Lüth S (February 2019). "Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy" . Drugs . 79 (Suppl 1): 23–29. doi :10.1007/s40265-018-1023-2 . PMC 6416235 . PMID 30706424 .
^ a b Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY (May 2018). "L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis" . The Cochrane Database of Systematic Reviews . 5 (5): CD012410. doi :10.1002/14651858.CD012410.pub2 . PMC 6494563 . PMID 29762873 .